A new study highlights an essential issue for women taking popular weight-loss and diabetic medications such as Ozempic and Wegovy before pregnancy. According to research, quitting these drugs to conceive is related to much more weight gain during pregnancy, which is linked to an increased risk of problems. 

The study, which looked at more than 150,000 pregnancies, found that women who stopped taking these medications, called GLP-1 receptor agonists (GLP-1RAs), gained an average of 3.3 kg more during their pregnancy compared to similar women who continued using them. 

This additional weight gain was more than simply a number on the scale. It was associated with a tangible rise in health risks. The study found that prior GLP-1RA usage was associated with an increased risk of preterm birth, gestational diabetes, and high blood pressure issues during pregnancy. 

GLP-1 medications mimic a natural hormone that regulates blood sugar, slows digestion, and signals to the brain when you're full. They are quite effective for managing diabetes and obesity. However, because the long-term consequences on a growing baby are uncertain, medical guidelines require women to cease taking them before attempting to conceive. 

This is where the new research uncovers a potential issue. When you stop taking the drug, the effects fade off. The study suggests that the body may "rebound," resulting in increased appetite and weight gain—a behaviour already observed in non-pregnant users who cease medication. During pregnancy, this reaction appears to translate straight into acquiring more weight than is recommended. 

The study compared women who used GLP-1RAs before pregnancy to a closely matched control group, ensuring a fair comparison based on age, weight, and pre-existing health issues. 

Weight Gain: The GLP-1 group gained 13.7 kg on average, compared to 10.5 kg in the non-GLP-1 group. Health Risks: They had a 34% higher risk of premature birth, a 30% higher risk of gestational diabetes, and a 29% higher risk of hypertensive diseases such as preeclampsia. 

The study authors noted that stopping GLP-1RA might cancel out or lessen the good effects of losing weight before pregnancy, suggesting that quick weight gain afterward could overshadow those benefits. 

Women of reproductive age are increasingly using these highly effective medications, making this research crucial. It does not imply that the medications are inherently hazardous, but it does highlight an important effect of discontinuing them during pregnancy. 

The findings offer new information to clinicians and people planning families. It emphasises the importance of thorough pre-pregnancy counselling and strict monitoring of weight gain throughout pregnancy for individuals who have recently discontinued these drugs. The report recommends greater research into ways for managing the rebound impact and protecting the health of both mother and infant.